1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2527)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5914)
  2. GSK Faculty (5697)
  3. Department of Medicine (4259)
  4. Department of Pathology and Laboratory Medicine (3037)
  5. Tow Center for Developmental Oncology (TCDO) (2613)
  6. Solid Tumor Oncology Division (2600)

More Groups

People
  1. Marc Ladanyi (1327)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (120)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (263)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (758)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5914)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Expression profiling of phenotypic and molecular heterogeneity in synovial sarcoma: Global transcriptional differences between SYT-SSX1 and SYT-SSX2 and use of RNAi to define transcriptional effects of SYT-SSX
    Meeting Abstract

    Saito, T.; Olshen, A. B.; Argani, P.; Ladanyi, M.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Cyclin D expression and G1 progression are dependent on MEK-MAP kinase activity in tumor cells with B-Raf mutation but not in breast cancer cells with wild type Ras and Raf
    Meeting Abstract

    Pratilas, C. A.; Grbovic, O.; Basso, A. D.; Sawai, A.; Chapman, P.; Rosen, N.; Solit, D. B.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Activated, mutated B-raf protein kinase requires the HSP90 chaperone for folding and stability and is degraded in response to HSP90 inhibitors
    Meeting Abstract

    Grbovic, O. M.; Basso, A. D.; Friedlander, P.; Houghton, A.; Solit, D. B.; Rosen, N.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Combinatorial targeting of oncogenesis via a novel rationally designed Hsp90 inhibitor
    Meeting Abstract

    Chiosis, G.; Solit, D.; Vilenchik, M.; Rosen, N.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • 17-allylamino-17-demethoxygeldanamycin (17-AAG) abrogates the G(2)/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective p53 to topoisomerase I poison
    Meeting Abstract

    Tse, A. N.; Solit, D.; Rosen, N.; Schwartz, G.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygaidanamycin)
    Meeting Abstract

    Solit, D. B.; Egorin, M.; Valentin, G.; Delacruz, A.; Ye, Q.; Schwartz, L.; Larson, S.; Rosen, N.; Scher, H. I.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Expression profiling of phenotypic and molecular heterogeneity in synovial sarcoma: Global transcriptional differences between SYT-SSX1 and SYT-SSX2 and use of RNAi to define transcriptional effects of SYT-SSX
    Meeting Abstract

    Saito, T.; Olshen, A. B.; Argani, P.; Ladanyi, M.
    FASEB Journal (2004)

    Fulltext@MSK | Save
  • AML patients lacking KIR ligand for donor KIR exhibit increased overall survival in HLA-identical sibling transplants
    Meeting Abstract

    Hsu, K. C.; Taylor, C. A.; O'Reilly, R. J.; Horowitz, M. M.; Arkun, K.; Pinto, C.; Dupont, B.
    Biology of Blood and Marrow Transplantation (2004)

    Fulltext@MSK | Save
  • A phase II trial of a non-myeloablative regimen combining in vivo T cell depletion with an anti-CD52 monoclonal antibody (alemtuzumab), and chemotherapy with fludarabine and melphalan prior to a related or unrelated hematopoietic stem cell transplantation
    Meeting Abstract

    Castro-Malaspina, H.; Papadopoulos, E.; Jakubowski, A.; Perales, M. A.; Young, J.; Hsu, K.; Boulad, F.; Prasad, V.; Small, T.; Kernan, N.; more...
    Biology of Blood and Marrow Transplantation (2004)

    Fulltext@MSK | Save
  • A phase II trial of busulfan, melphalan, and fludarabine followed by allogeneic T-cell depleted hematopoietic stem cell transplants from HLA-identical, or HLA-non identical related or unrelated donors for the treatment of advanced hematopoietic malignancies
    Meeting Abstract

    Boulad, F.; Jakubowski, A.; Castro-Malaspina, H.; Hsu, K. C.; Kernan, N. A.; Papadopoulos, E. B.; Perales, M. A.; Prockop, S. E.; Small, T. N.; van den Brink, M. R. M.; more...
    Blood (2004)

    Fulltext@MSK | Save